Which has higher earnings and valuation, ACTU or GELS?

Gelteq has higher revenue and earnings than Actuate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A Gelteq $110K 56.47 -$4.30M N/A N/A

Is ACTU or GELS more profitable?

Gelteq's return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -270.99% -150.91% Gelteq N/A N/A N/A

Do analysts prefer GELS or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, GELS or TXMD?

TherapeuticsMD has higher revenue and earnings than Gelteq. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 56.47 -$4.30M N/A N/A TherapeuticsMD $3.02M 7.93 -$570K $0.06 34.50

Do analysts prefer ABVC or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ABVC or GELS?

Gelteq has lower revenue, but higher earnings than ABVC BioPharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ABVC BioPharma $510K 46.85 -$7.91M -$0.30 N/A Gelteq $110K 56.47 -$4.30M N/A N/A

Is ABVC or GELS more profitable?

Gelteq's return on equity of 0.00% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -47.68% -30.97% Gelteq N/A N/A N/A

Do analysts recommend PLRZ or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, PLRZ or GELS?

Polyrizon has higher earnings, but lower revenue than Gelteq. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polyrizon N/A N/A -$3.34M N/A N/A Gelteq $110K 56.47 -$4.30M N/A N/A

Is PLRZ or GELS more profitable?

Company Net Margins Return on Equity Return on Assets Polyrizon N/A N/A N/A Gelteq N/A N/A N/A

Do analysts recommend CLRB or GELS?

Cellectar Biosciences currently has a consensus target price of $11.00, suggesting a potential upside of 323.08%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Cellectar Biosciences is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, CLRB or GELS?

Gelteq has higher revenue and earnings than Cellectar Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$3.84 N/A Gelteq $110K 56.47 -$4.30M N/A N/A

Is CLRB or GELS more profitable?

Gelteq's return on equity of 0.00% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -185.35% -115.42% Gelteq N/A N/A N/A

Gelteq (GELS) Competitors

$0.58 0.00 (-0.17%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.59 +0.01 (+2.41%)

As of 08/14/2026 07:48 PM Eastern

Compare

GELS vs. ACTU, TXMD, ABVC, PLRZ, and CLRB

Should you buy Gelteq stock or one of its competitors? Gelteq's main competitors and comparable companies include Actuate Therapeutics (ACTU), TherapeuticsMD (TXMD), ABVC BioPharma (ABVC), Polyrizon (PLRZ), and Cellectar Biosciences (CLRB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Gelteq compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

Actuate Therapeutics presently has a consensus target price of $13.67, suggesting a potential upside of 1,253.14%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Actuate Therapeutics is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gelteq's return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-270.99%	-150.91%
Gelteq	N/A	N/A	N/A

In the previous week, Actuate Therapeutics had 3 more articles in the media than Gelteq. MarketBeat recorded 4 mentions for Actuate Therapeutics and 1 mentions for Gelteq. Gelteq's average media sentiment score of 1.87 beat Actuate Therapeutics' score of 1.47 indicating that Gelteq is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Positive
Gelteq	Very Positive

Actuate Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.44, suggesting that its stock price is 144% less volatile than the broader market.

Gelteq has higher revenue and earnings than Actuate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Gelteq	$110K	56.47	-$4.30M	N/A	N/A

Summary

Actuate Therapeutics and Gelteq tied by winning 5 of the 10 factors compared between the two stocks.

How does Gelteq compare to TherapeuticsMD?

Gelteq (NASDAQ:GELS) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TherapeuticsMD has higher revenue and earnings than Gelteq.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	56.47	-$4.30M	N/A	N/A
TherapeuticsMD	$3.02M	7.93	-$570K	$0.06	34.50

Gelteq has a beta of -0.44, suggesting that its share price is 144% less volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

30.7% of TherapeuticsMD shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Gelteq has a net margin of 0.00% compared to TherapeuticsMD's net margin of -6.64%. Gelteq's return on equity of 0.00% beat TherapeuticsMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
TherapeuticsMD	-6.64%	-1.09%	-0.78%

In the previous week, TherapeuticsMD had 1 more articles in the media than Gelteq. MarketBeat recorded 2 mentions for TherapeuticsMD and 1 mentions for Gelteq. TherapeuticsMD's average media sentiment score of 2.43 beat Gelteq's score of 1.87 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Gelteq	Very Positive
TherapeuticsMD	Very Positive

Summary

TherapeuticsMD beats Gelteq on 7 of the 11 factors compared between the two stocks.

How does Gelteq compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation and risk.

Gelteq has lower revenue, but higher earnings than ABVC BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	46.85	-$7.91M	-$0.30	N/A
Gelteq	$110K	56.47	-$4.30M	N/A	N/A

11.4% of ABVC BioPharma shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

ABVC BioPharma has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.44, indicating that its share price is 144% less volatile than the broader market.

In the previous week, ABVC BioPharma had 1 more articles in the media than Gelteq. MarketBeat recorded 2 mentions for ABVC BioPharma and 1 mentions for Gelteq. ABVC BioPharma's average media sentiment score of 2.43 beat Gelteq's score of 1.87 indicating that ABVC BioPharma is being referred to more favorably in the media.

Company	Overall Sentiment
ABVC BioPharma	Very Positive
Gelteq	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gelteq's return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Gelteq	N/A	N/A	N/A

Summary

ABVC BioPharma beats Gelteq on 6 of the 10 factors compared between the two stocks.

How does Gelteq compare to Polyrizon?

Polyrizon (NASDAQ:PLRZ) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, risk, dividends and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Polyrizon has higher earnings, but lower revenue than Gelteq.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A
Gelteq	$110K	56.47	-$4.30M	N/A	N/A

In the previous week, Polyrizon and Polyrizon both had 1 articles in the media. Polyrizon's average media sentiment score of 1.89 beat Gelteq's score of 1.87 indicating that Polyrizon is being referred to more favorably in the media.

Company	Overall Sentiment
Polyrizon	Very Positive
Gelteq	Very Positive

Company	Net Margins	Return on Equity	Return on Assets
Polyrizon	N/A	N/A	N/A
Gelteq	N/A	N/A	N/A

Polyrizon has a beta of -1.5, suggesting that its share price is 250% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.44, suggesting that its share price is 144% less volatile than the broader market.

Summary

Polyrizon and Gelteq tied by winning 2 of the 4 factors compared between the two stocks.

How does Gelteq compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Gelteq (NASDAQ:GELS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Cellectar Biosciences currently has a consensus target price of $11.00, suggesting a potential upside of 323.08%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe Cellectar Biosciences is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Cellectar Biosciences had 8 more articles in the media than Gelteq. MarketBeat recorded 9 mentions for Cellectar Biosciences and 1 mentions for Gelteq. Gelteq's average media sentiment score of 1.87 beat Cellectar Biosciences' score of 0.21 indicating that Gelteq is being referred to more favorably in the news media.

Company	Overall Sentiment
Cellectar Biosciences	Neutral
Gelteq	Very Positive

Gelteq's return on equity of 0.00% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-185.35%	-115.42%
Gelteq	N/A	N/A	N/A

Gelteq has higher revenue and earnings than Cellectar Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$3.84	N/A
Gelteq	$110K	56.47	-$4.30M	N/A	N/A

16.4% of Cellectar Biosciences shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cellectar Biosciences has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.44, suggesting that its stock price is 144% less volatile than the broader market.

Summary

Cellectar Biosciences beats Gelteq on 8 of the 13 factors compared between the two stocks.

Get Gelteq News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GELS vs. The Competition

Export

Metric	Gelteq	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.21M	$11.83B	$7.04B	$13.06B
Dividend Yield	N/A	2.69%	2.56%	10.63%
P/E Ratio	N/A	641.79	210.89	21.68
Price / Sales	56.47	744.01	603.84	93.83
Price / Cash	N/A	15.13	28.87	38.43
Price / Book	0.54	10.38	11.17	6.52
Net Income	-$4.30M	$2.77B	$3.45B	$346.94M
7 Day Performance	3.96%	0.18%	1.17%	1.08%
1 Month Performance	-1.53%	0.70%	2.18%	1.87%
1 Year Performance	-56.39%	145.73%	62.39%	20.79%

Gelteq Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GELS Gelteq	1.2733 of 5 stars	$0.58 -0.2%	N/A	-56.4%	$6.21M	$110K	N/A	N/A	Positive News Gap Up
ACTU Actuate Therapeutics	3.7461 of 5 stars	$1.01 +3.6%	$13.67 +1,253.1%	-87.6%	$24.17M	N/A	N/A	10	News Coverage Positive News Earnings Report Short Interest Decrease
TXMD TherapeuticsMD	1.9601 of 5 stars	$2.07 -0.5%	N/A	+76.9%	$23.96M	$3.02M	34.50	420	Positive News Earnings Report Analyst Upgrade
ABVC ABVC BioPharma	1.0082 of 5 stars	$0.90 -6.2%	N/A	-72.7%	$23.90M	$510K	N/A	30	Positive News Earnings Report Upcoming Earnings
PLRZ Polyrizon	0.9101 of 5 stars	$10.98 +2.1%	N/A	+66.4%	$22.88M	N/A	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GELS) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gelteq (GELS) Competitors

GELS vs. ACTU, TXMD, ABVC, PLRZ, and CLRB

How does Gelteq compare to Actuate Therapeutics?

Summary

How does Gelteq compare to TherapeuticsMD?

Summary

How does Gelteq compare to ABVC BioPharma?

Summary

How does Gelteq compare to Polyrizon?

Summary

How does Gelteq compare to Cellectar Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gelteq (GELS) Competitors

GELS vs. ACTU, TXMD, ABVC, PLRZ, and CLRB

How does Gelteq compare to Actuate Therapeutics?

Do analysts prefer ACTU or GELS?

Is ACTU or GELS more profitable?

Does the media favor ACTU or GELS?

Which has more volatility and risk, ACTU or GELS?

Which has higher earnings and valuation, ACTU or GELS?

Summary

How does Gelteq compare to TherapeuticsMD?

Do analysts prefer GELS or TXMD?

Which has better earnings & valuation, GELS or TXMD?

Which has more risk & volatility, GELS or TXMD?

Do institutionals & insiders believe in GELS or TXMD?

Is GELS or TXMD more profitable?

Does the media prefer GELS or TXMD?

Summary

How does Gelteq compare to ABVC BioPharma?

Which has stronger valuation & earnings, ABVC or GELS?

Do insiders & institutionals have more ownership in ABVC or GELS?

Which has more volatility & risk, ABVC or GELS?

Does the media refer more to ABVC or GELS?

Do analysts prefer ABVC or GELS?

Is ABVC or GELS more profitable?

Summary

How does Gelteq compare to Polyrizon?

Do analysts recommend PLRZ or GELS?

Which has stronger earnings & valuation, PLRZ or GELS?

Does the media prefer PLRZ or GELS?

Is PLRZ or GELS more profitable?

Which has more risk and volatility, PLRZ or GELS?

Summary

How does Gelteq compare to Cellectar Biosciences?

Do analysts recommend CLRB or GELS?

Does the media favor CLRB or GELS?

Is CLRB or GELS more profitable?

Which has better valuation and earnings, CLRB or GELS?

Do insiders and institutionals hold more shares of CLRB or GELS?

Which has more volatility & risk, CLRB or GELS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools